Neuroprotective Potential of Peroxisome Proliferator Activated Receptor-α Agonist in Cognitive Impairment in Parkinson’s Disease: Behavioral, Biochemical, and PBPK Profile

Figure 3

(a) Effect of fenofibrate on TNF-𝛼, (b) IL-6 level in different groups. ^∗∗∗𝑃<0.001 MPTP versus sham, ^@@@𝑃<0.001 MPTP + vehicle versus sham; ^##𝑃<0.01, ^###𝑃<0.001 MPTP versus feno 10, 30, and 100 mg/kg treated groups; and ^††𝑃<0.01, ^†††𝑃<0.001 MPTP + vehicle versus feno 10, 30, and 100 mg/kg groups. All readings are expressed as mean ± SEM (𝑛=3).

(a)

(b)